S. 355 · 119th Congress · Senate

FDA Modernization Act 3.0

In Congress· Message on Senate action sent to the House.
Introduced
Feb 3, 25
Passed Senate
Dec 16, 25
Passed House
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

FDA Modernization Act 3.0

This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. 

The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications, and may make other changes to the regulations as appropriate. 

The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule. 

Action Timeline

9
  1. DEC 17, 2025House floor actions

    Held at the desk.

  2. DEC 17, 2025House floor actions

    Received in the House.

  3. DEC 17, 2025Senate

    Message on Senate action sent to the House.

  4. DEC 16, 2025Senate

    Passed Senate with an amendment by Unanimous Consent

    (text of amendment in the nature of a substitute: CR S8794)

  5. DEC 16, 2025Library of Congress

    Passed/agreed to in Senate

    Passed Senate with an amendment by Unanimous Consent.

  6. DEC 16, 2025Senate

    Measure laid before Senate by unanimous consent

    (consideration: CR S8793-8794)

    8793Yea
    8794Nay
    0NV
  7. DEC 16, 2025Library of Congress

    Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.

  8. FEB 03, 2025Senate

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

  9. FEB 03, 2025Library of Congress

    Introduced in Senate

Committees

1

Health, Education, Labor, and Pensions Committee

sshr00

Referred: Dec 17, 2025

Active